C1-INH and its Effect on Infarct Size and Ventricular Function in an Acute Pig Model of Infarction, Cardiopulmonary Bypass, and Reperfusion

Abstract

Background: Recent studies suggest that complement inhibition reduces reperfusion injury. A clinical setting with local application of a C1 esterase inhibitor (C1-INH) has been modeled in an animal study in order to further investigate these findings. Methods: In 21 pigs, the left anterior descending coronary artery (LAD) was occluded distally to the first diagonal branch for 2 hours (h), including 1 h of cardioplegic arrest during CPB. After release of the coronary snare, C1-INH or NaCl (control) was applied to the aortic root. Thereafter, the aortic cross-clamp was removed and the heart was reperfused for 30 minutes before weaning from CPB. Left ventricular pressure volume analysis was performed by a multielectrode conductance catheter and the area at risk and infarct size were determined from excised hearts. Results: The following data were observed (mean ± SEM) for the control group and the C1-INH group, respectively, after 1-h ligation of the LAD: heart rate (HR) 86 ± 3 and 93 ± 6 beats/min, stroke volume (SV) 1.2 ± 0.1 and 1.2 ± 0.1 ml/kg, aortic pressure (AoP) 83 ± 6 and 87 ± 5 mmHg, left ventricular end-diastolic pressure (LVedP) 12 ± 1 and 11 ± 2 mmHg; two hours after weaning from CPB: HR 106 ± 9 and 123 ± 4 beats/min, SV 0.9 ± 0.1 and 0.9 ± 0.1 ml/kg, AoP 65 ± 5 and 79 ± 7 mmHg, LVedP 9 ± 1 and 8 ± 1 mmHg. Conductance catheter measurements showed no improved left ventricular performance after C1-INH application. Infarct size to area at risk ratio was 61.5 ± 4.2 % for controls and 61.4 ± 4.8 % for C1-INH. Conclusions: Intracoronary application of complement inhibitor in an acute infarction model, which mimicked a clinical setting of urgent coronary bypass grafting after ischemia, has been shown to neither influence the area of infarction, nor the ventricular function.

Key words

Infarction - reperfusion - complement inhibition - cardiopulmonary bypass

References

• 1 Schäfer H J, Mathey D, Hugo F, Bhakdi S. Deposition of the terminal C5 b-9 complement complex in infarcted areas of human myocardium.  J Immunol. 1986;  137 1945-1949
• 2 Rossen R D, Michael L H, Kagiyama A, Savage H E, Hanson G, Reisberg M A. et al . Mechanism of complement activation after coronary artery occlusion: evidence that myocardial ischemia in dogs causes release of constituents of myocardial subcellular origin that complex with human C1 q in vivo.  Circ Res. 1988;  62 572-584
• 3 Maroko P R, Carpenter C B, Chiareillo M. Reduction by cobra venom factor of myocardial necrosis after coronary artery occlusion.  J Clin Invest. 1978;  61 661-670
• 4 Tsao P S, Aoki N, Lefer D J, Johnson 3rd G, Lefer A M. Time course of endothelial dysfunction and myocardial injury during myocardial ischemia and reperfusion in the cat.  Circul. 1990;  82 1402-1412
• 5 Crawford M H, Grover F L, Kolb W P, McMahan C A, O'Rourke R A, McManus L M. et al . Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury.  Circul. 1988;  78 144-148
• 6 Mathey D, Schofer J, Schafer H J, Hamdoch T, Joachim H C, Ritgen A. et al . Early accumulation of the terminal complement complex in the ischemic myocardium after reperfusion.  Eur Heart J. 1994;  15 418-423
• 7 Shandelya S M, Kuppusamy P, Herskowitz A, Weisfeldt M L, Zweier J L. Soluble complement receptor type 1 inhibits the complement pathway and prevents contractile failure in the postischemic heart.  Circul. 1993;  88 2812-2826
• 8 Weisman H F, Bartow T, Leppo M K, Marsh Jr H C, Carson G R, Concino M F. et al . Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.  Sci. 1990;  13 146-151
• 9 Gillinov A M, DeValeria P A, Winkelstein J A, Wilson I, Curtis W E, Shaw D. et al . Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass.  Ann Thorac Surg. 1993;  55 619-624
• 10 Buerke M, Murohara T, Lefer A M. Cardioprotective effects of a C1 esterase inhibitor in myocardial ischemia and reperfusion.  Circul. 1995;  91 393-302
• 11 Horstick G, Heimann A, Gotze O, Hafner G, Berg O, Boehmer P. et al . Intracoronary application of C1 esterase inhibitor improves cardiac function and reduces myocardial necrosis in an experimental model of ischemia and reperfusion.  Circul. 1997;  95 701-708
• 12 Buerke M, Prufer D, Dahm M, Oelert H, Meyer J, Darius H. Blocking of classical complement pathway inhibits endothelial adhesion molecule expression and preserves ischemic myocardium from reperfusion injury.  J Pharmacol Exp Ther. 1998;  286 429-438
• 13 Lazar H L, Hamasaki T, Bao Y, Rivers S, Bernard S A, Shemin R J. Soluble complement receptor type I limits damage during revascularization of ischemic myocardium.  Ann Thorac Surg. 1998;  65 973-977
• 14 Lazar H L, Bao Y, Gaudiani J, Rivers S, Marsh H. Total complement inhibition. An effective strategy to limit ischemic injury during coronary revascularization on cardiopulmonary bypass.  Circulation. 1999;  100 1438-1442
• 15 Horstick G, Berg O, Heimann A, Gotze O, Loos M, Hafner G. et al . Application of C1-esterase inhibitor during reperfusion of ischemic myocardium. Dose-related beneficial versus detrimental effects.  Circul. 2001;  104 3125-3131
• 16 Bauernschmitt R, Bohrer H, Hagl S. Rescue therapy with C1-esterase inhibitor concentrate after emergency coronary surgery for failed PTCA.  Intensive Care Med. 1998;  24 635-638
• 17 Baan J, van der Velde E T, de Bruin H G, Smeenk G J, Koops J, van Dijk A D. et al . Continuous measurement of left ventricular volume in animals and humans by conductance catheter.  Circul. 1984;  70 812-823
• 18 Warltier D C, Zyvoloski M G, Gross G J, Hardman H F, Brooks H L. Determination of experimental myocardial infarct size.  J Pharmacol Meth. 1981;  6 199-210
• 19 Libby P, Maroko P R, Bloor C M, Sobel B E, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration.  Clin Invest. 1973;  52 599-607
• 20 Entman M L, Michael L, Rossen R D, Dreyer W J, Anderson D C, Taylor A A, Smith C W. Inflammation in the course of early myocardial ischemia.  FASEB J. 1991;  5 2529-2537
• 21 Baan J, Jong T T, Kerkhof P L, Moene R J, van Dijk A D, van der Velde E T. et al . Continuous stroke volume and cardiac output from intra-ventricular dimensions obtained with impedance catheter.  Cardiovasc Res. 1981;  15 328-334
• 22 Burkhoff D, van der Velde E, Kass D, Baan J, Maughan W L, Sagawa K. Accuracy of volume measurement by conductance catheter in isolated, ejecting canine hearts.  Circul. 1985;  72 440-447
• 23 Kass D A, Yamazaki T, Burkhoff D, Maughan W L, Sagawa K. Determination of left ventricular end-systolic pressure-volume relationships by the conductance (volume) catheter technique.  Circul. 1986;  73 586-595
• 24 Dickstein M L, Yano O, Spotnitz H M, Burkhoff D. Assessment of right ventricular contractile state with the conductance catheter technique in the pig.  Cardiovasc Res. 1995;  29 820-826
• 25 Nordhaug D, Steensrud T, Korvald C, Aghajani E, Myrmel T. Preserved myocardial energetics in acute ischemic left ventricular failure - studies in an experimental pig model.  Eur J Cardiothorac Surg. 2002;  22 135-142
• 26 White P A, Chaturvedi R R, Shore D, Lincoln C, Szwarc R S, Bishop A J. et al . Left ventricular parallel conductance during cardiac cycle in children with congenital heart disease.  Am J Physiol. 1997;  273 H295-H302
• 27 Chaturvedi R R, Shore D F, Lincoln C, Mumby S, Kemp M, Brierly J. et al . Acute right ventricular restrictive physiology after repair of tetralogy of Fallot: association with myocardial injury and oxidative stress.  Circul. 1999;  100 540-547
• 28 Chaturvedi R R, Shore D F, White P A, Scallan M H, Gothard J W, Redington A N. et al . Modified ultrafiltration improves global left ventricular systolic function after open-heart surgery in infants and children.  Eur J Cardiothorac Surg. 1999;  15 742-746
• 29 Korvald C, Elvenes O P, Aghajani E, Myhre E S, Myrmel T. Postischemic mechanoenergetic inefficiency is related to contractile dysfunction and not altered metabolism.  Am J Physiol. 2001;  281 H2645-H2653
• 30 Kirklin J K, Westaby S, Blackstone E H, Kirklin J W, Chenoweth D E, Pacifico A D. Complement and the damaging effects of cardiopulmonary bypass.  J Thorac Cardiovasc Surg. 1983;  86 845-857
• 31 Seghaye M C, Duchateau J, Grabitz R G, Faymonville M L, Messmer B J, Buro-Rathsmann K, von Bernuth G. Complement activation during cardiopulmonary bypass in infants and children. Relation to postoperative multiple system organ failure.  J Thorac Cardiovasc Surg. 1993;  106 978-987
• 32 Paparella D, Yau T M, Young E. Cardiopulmonary bypass induced inflammation: pathophysiology and treatment. An update.  Eur J Cardiothorac Surg. 2002;  21 232-244
• 33 Chai P J, Nassar R, Oakeley A E, Craig D M, Quick Jr G, Jaggers J. et al . Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage.  Circul. 2000;  101 541-546